VIMIAN logo

Vimian Group AB (publ) Stock Price

OM:VIMIAN Community·SEK 13.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

VIMIAN Share Price Performance

SEK 25.52
-14.53 (-36.28%)
SEK 33.76
Fair Value
SEK 25.52
-14.53 (-36.28%)
24.4% undervalued intrinsic discount
SEK 33.76
Fair Value
Price SEK 25.52
AnalystConsensusTarget SEK 33.76
AnalystLowTarget SEK 25.09
AnalystHighTarget SEK 41.10

VIMIAN Community Narratives

AnalystConsensusTarget·
Fair Value SEK 33.76 24.4% undervalued intrinsic discount

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value SEK 25.09 1.7% overvalued intrinsic discount

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value SEK 41.1 37.9% undervalued intrinsic discount

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 25.09
1.7% overvalued intrinsic discount
Revenue
8.86% p.a.
Profit Margin
14.57%
Future PE
18.93x
Price in 2029
SEK 30.13
SEK 33.76
24.4% undervalued intrinsic discount
Revenue
8.71% p.a.
Profit Margin
17.69%
Future PE
21.28x
Price in 2029
SEK 40.35

Trending Discussion

Updated Narratives

VIMIAN logo

VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance

Fair Value: SEK 25.09 1.7% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VIMIAN logo

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Fair Value: SEK 41.1 37.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VIMIAN logo

VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade

Fair Value: SEK 33.76 24.4% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with proven track record.

0 Risks
3 Rewards

Vimian Group AB (publ) Key Details

€425.0m

Revenue

€132.2m

Cost of Revenue

€292.8m

Gross Profit

€261.5m

Other Expenses

€31.3m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 29, 2026
0.059
68.89%
7.36%
31.5%
View Full Analysis

About VIMIAN

Founded
2020
Employees
1200
CEO
Alireza Tajbakhsh
WebsiteView website
vimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Recent VIMIAN News & Updates

Recent updates

No updates